Clinical Report: New AASM Guidance on Chronic Insomnia Treatment
Overview
The American Academy of Sleep Medicine (AASM) guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as the preferred first-line treatment for chronic insomnia. Combination therapy with CBT-I and pharmacotherapy offers modest benefits over medication alone but does not improve outcomes compared to CBT-I alone.
Background
Chronic insomnia disorder affects many adults and requires effective management strategies. Treatment options include cognitive behavioral therapy for insomnia (CBT-I), pharmacotherapy, or a combination of both. The AASM conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the comparative effectiveness of these approaches. This guideline aims to clarify the role of combination therapy relative to established treatments.
Data Highlights
| Comparison | Outcome | Effect | Adverse Effects |
|---|---|---|---|
| Combination therapy vs Pharmacotherapy alone | Global insomnia severity, sleep continuity | Small, clinically meaningful improvements | Slightly higher rates, especially morning sleepiness |
| Combination therapy vs CBT-I alone | Insomnia severity, sleep continuity, daytime functioning | No clinically meaningful improvements | Not specified |
| Combination therapy (short-term) | Total sleep time (TST) | Short-term increase noted | Not clinically meaningful in other outcomes |
Key Findings
- CBT-I remains the preferred first-line treatment for chronic insomnia.
- Combination therapy provides modest benefits over pharmacotherapy alone but no meaningful improvement over CBT-I alone.
- Combination therapy is associated with slightly increased adverse effects, particularly morning sleepiness.
- Pharmacotherapy alone is appropriate when CBT-I is unavailable, unaffordable, or not feasible.
- Shared decision-making is emphasized to tailor treatment based on patient preferences, clinical priorities, and access.
- Evidence is limited by low certainty, short-term outcomes, and underrepresentation of diverse populations.
Clinical Implications
Clinicians should prioritize CBT-I as the first-line treatment for chronic insomnia, reserving combination therapy for patients needing rapid symptom relief or short-term increases in total sleep time. Pharmacotherapy alone remains a reasonable option when CBT-I cannot be accessed or tolerated. Shared decision-making is essential to balance effectiveness, patient preferences, and treatment availability.
Conclusion
The AASM guideline supports CBT-I as the cornerstone of chronic insomnia management, with combination therapy offering limited additional benefit over CBT-I alone. Treatment should be individualized, considering patient needs and access to care.
Related Resources & Content
- American Academy of Sleep Medicine 2024 -- New Guidance on Chronic Insomnia Treatment
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
